6 Aptamers for Targeted Therapy
169
81. Acquasaliente L, Peterle D, Tescari S, Pozzi N, Pengo V, De Filippis V (2016) Molecular
mapping of alpha-thrombin (alphaT)/beta2-glycoprotein I (beta2GpI) interaction reveals how
beta2GpI affects alphaT functions. Biochem J 473(24):4629–4650
82. Hughes QW, Le BT, Gilmore G, Baker RI, Veedu RN (2017) Construction of a bivalent
thrombin binding aptamer and its antidote with improved properties. Molecules 22(10):1770
83. Tasset DM, Kubik MF, Steiner W (1997) Oligonucleotide inhibitors of human thrombin that
bind distinct epitopes. J Mol Biol 272(5):688–698
84. Muller J, Becher T, Mayer G, Potzsch B (2016) Aptamer-Based Enzyme Capture Assay for
Measurement of Plasma Thrombin Levels. Methods Mol Biol 1380:179–189
85. Gribkova IV, Spiridonova VA, Gorbatenko AS, Denisov SS, Ataullakhanov FI, Sinauridze
EI (2014) Thrombin inhibitors based on single-stranded DNA aptamers. Blood Coagul
Fibrinolysis 25(1):39–45
86. Mazurov AV, Titaeva EV, Khaspekova SG, Storojilova AN, Spiridonova VA, Kopylov AM,
Dobrovolsky AB (2011) Characteristics of a new DNA aptamer, direct inhibitor of thrombin.
Bull Exp Biol Med 150(4):422–425
87. Troisi R, Napolitano V, Spiridonova V, Krauss IR, Sica F (2018) Several structural motifs cooperate in determining the highly effective anti-thrombin activity of NU172 aptamer. Nucleic
Acids Res 46(22):12177–12185
88. Lai WY, Wang JW, Huang BT, Lin EP, Yang PC (2019) A novel TNF-alpha-targeting aptamer
for TNF-alpha-mediated acute lung injury and acute liver failure. Theranostics 9(6):1741–
1751
89. Gery I, Gershon RK, Waksman BH (1972) Potentiation of the T-lymphocyte response to
mitogens. I. The responding cell. J Exp Med 136 (1):128–142
90. Dinarello CA, van der Meer JW (2013) Treating inflammation by blocking interleukin-1 in
humans. Semin Immunol 25(6):469–484
91. Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MC (2013) Intracellular interleukin-1
receptor 2 binding prevents cleavage and activity of interleukin-1alpha, controlling necrosisinduced sterile inflammation. Immunity 38(2):285–295
92. Ren X, Gelinas AD, von Carlowitz I, Janjic N, Pyle AM (2017) Structural basis for IL-1alpha
recognition by a modified DNA aptamer that specifically inhibits IL-1alpha signaling. Nat
Commun 8(1):810
93. Roufosse F (2018) Targeting the interleukin-5 pathway for treatment of eosinophilic
conditions other than asthma. Front Med-Lausanne 5 (2296–858X Print):49
94. Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW (2001) Th2 cytokines and
asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res 2 (2):71–79
95. Menzella F, Lusuardi M, Galeone C, Taddei S, Facciolongo N, Zucchi L (2016) Mepolizumab
for severe refractory eosinophilic asthma: evidence to date and clinical potential. Ther Adv
Chronic Dis 7(6):260–277
96. Jamalvandi M, Khanahmad H, Irani S, Bastaminezhad S (2019) Selection and characterization
of single-stranded DNA aptamers against interleukin-5. Res Pharm Sci 14(6):515–523
97. Kishimoto T (2005) Interleukin-6: from basic science to medicine–40 years in immunology.
Annu Rev Immunol 23 (0732–0582 Print):1–21
98. Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol
16(5):448–457
99. Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted
therapy for cancer. Cancer Treat Rev 38(7):904–910
100. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type
cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334(Pt 2):297–314
101. Tanaka T, Narazaki M, Kishimoto T (2012) Therapeutic targeting of the interleukin-6 receptor.
Annu Rev Pharmacol Toxicol 52 (1545–4304 Electronic):199–219
102. Kopf M, Bachmann MF, Marsland BJ (2010) Averting inflammation by targeting the cytokine
environment. Nat Rev Drug Discov 9(9):703–718
103. Hirota M, Murakami I, Ishikawa Y, Suzuki T, Sumida S, Ibaragi S, Kasai H, Horai N, Drolet
DW, Gupta S, Janjic N, Schneider DJ (2016) Chemically modified interleukin-6 aptamer
169
81. Acquasaliente L, Peterle D, Tescari S, Pozzi N, Pengo V, De Filippis V (2016) Molecular
mapping of alpha-thrombin (alphaT)/beta2-glycoprotein I (beta2GpI) interaction reveals how
beta2GpI affects alphaT functions. Biochem J 473(24):4629–4650
82. Hughes QW, Le BT, Gilmore G, Baker RI, Veedu RN (2017) Construction of a bivalent
thrombin binding aptamer and its antidote with improved properties. Molecules 22(10):1770
83. Tasset DM, Kubik MF, Steiner W (1997) Oligonucleotide inhibitors of human thrombin that
bind distinct epitopes. J Mol Biol 272(5):688–698
84. Muller J, Becher T, Mayer G, Potzsch B (2016) Aptamer-Based Enzyme Capture Assay for
Measurement of Plasma Thrombin Levels. Methods Mol Biol 1380:179–189
85. Gribkova IV, Spiridonova VA, Gorbatenko AS, Denisov SS, Ataullakhanov FI, Sinauridze
EI (2014) Thrombin inhibitors based on single-stranded DNA aptamers. Blood Coagul
Fibrinolysis 25(1):39–45
86. Mazurov AV, Titaeva EV, Khaspekova SG, Storojilova AN, Spiridonova VA, Kopylov AM,
Dobrovolsky AB (2011) Characteristics of a new DNA aptamer, direct inhibitor of thrombin.
Bull Exp Biol Med 150(4):422–425
87. Troisi R, Napolitano V, Spiridonova V, Krauss IR, Sica F (2018) Several structural motifs cooperate in determining the highly effective anti-thrombin activity of NU172 aptamer. Nucleic
Acids Res 46(22):12177–12185
88. Lai WY, Wang JW, Huang BT, Lin EP, Yang PC (2019) A novel TNF-alpha-targeting aptamer
for TNF-alpha-mediated acute lung injury and acute liver failure. Theranostics 9(6):1741–
1751
89. Gery I, Gershon RK, Waksman BH (1972) Potentiation of the T-lymphocyte response to
mitogens. I. The responding cell. J Exp Med 136 (1):128–142
90. Dinarello CA, van der Meer JW (2013) Treating inflammation by blocking interleukin-1 in
humans. Semin Immunol 25(6):469–484
91. Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MC (2013) Intracellular interleukin-1
receptor 2 binding prevents cleavage and activity of interleukin-1alpha, controlling necrosisinduced sterile inflammation. Immunity 38(2):285–295
92. Ren X, Gelinas AD, von Carlowitz I, Janjic N, Pyle AM (2017) Structural basis for IL-1alpha
recognition by a modified DNA aptamer that specifically inhibits IL-1alpha signaling. Nat
Commun 8(1):810
93. Roufosse F (2018) Targeting the interleukin-5 pathway for treatment of eosinophilic
conditions other than asthma. Front Med-Lausanne 5 (2296–858X Print):49
94. Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW (2001) Th2 cytokines and
asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res 2 (2):71–79
95. Menzella F, Lusuardi M, Galeone C, Taddei S, Facciolongo N, Zucchi L (2016) Mepolizumab
for severe refractory eosinophilic asthma: evidence to date and clinical potential. Ther Adv
Chronic Dis 7(6):260–277
96. Jamalvandi M, Khanahmad H, Irani S, Bastaminezhad S (2019) Selection and characterization
of single-stranded DNA aptamers against interleukin-5. Res Pharm Sci 14(6):515–523
97. Kishimoto T (2005) Interleukin-6: from basic science to medicine–40 years in immunology.
Annu Rev Immunol 23 (0732–0582 Print):1–21
98. Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol
16(5):448–457
99. Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted
therapy for cancer. Cancer Treat Rev 38(7):904–910
100. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type
cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334(Pt 2):297–314
101. Tanaka T, Narazaki M, Kishimoto T (2012) Therapeutic targeting of the interleukin-6 receptor.
Annu Rev Pharmacol Toxicol 52 (1545–4304 Electronic):199–219
102. Kopf M, Bachmann MF, Marsland BJ (2010) Averting inflammation by targeting the cytokine
environment. Nat Rev Drug Discov 9(9):703–718
103. Hirota M, Murakami I, Ishikawa Y, Suzuki T, Sumida S, Ibaragi S, Kasai H, Horai N, Drolet
DW, Gupta S, Janjic N, Schneider DJ (2016) Chemically modified interleukin-6 aptamer